Hubbry Logo
Elizabeth HolmesElizabeth HolmesMain
Open search
Elizabeth Holmes
Community hub
Elizabeth Holmes
logo
20 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Elizabeth Holmes
Elizabeth Holmes
Elizabeth Holmes
View on Wikipedia
from Wikipedia

Elizabeth Anne Holmes (born February 3, 1984) is an American biotechnology entrepreneur who was convicted of fraud in connection with her blood-testing company, Theranos.[2] The company's valuation soared after it claimed to have revolutionized blood testing by developing methods that needed only very small volumes of blood, such as from a fingerprick.[3][4] In 2015, Forbes had named Holmes the youngest and wealthiest self-made female billionaire in the United States on the basis of a $9-billion valuation of her company.[5] In the following year, as revelations of fraud about Theranos's claims began to surface, Forbes revised its estimate of Holmes's net worth to zero,[6] and Fortune named her in its feature article on "The World's 19 Most Disappointing Leaders".[7]

Key Information

The decline of Theranos began in 2015, when a series of journalistic and regulatory investigations revealed doubts about the company's claims and whether Holmes had been truthful with investors and the government. In 2018, the U.S. Securities and Exchange Commission (SEC) charged Theranos, Holmes, and former Theranos chief operating officer (COO) Ramesh "Sunny" Balwani with raising $700 million from investors through a fraud involving false or exaggerated claims about the accuracy of the company's blood-testing technology; Holmes settled the charges by paying a $500,000 fine, returning 18.9 million shares to the company, relinquishing her voting control of Theranos, and accepting a ten-year ban from serving as an officer or director of a public company.

Holmes was in a clandestine romantic relationship with Balwani throughout most of Theranos's history.[8] Holmes and Balwani jointly ran the company with a "dysfunctional corporate culture" of "secrecy and fear" according to employees.[9] Staff also claimed that those who "raised concerns or objections" were "usually marginalized or fired" by the pair.[9] Following the collapse of Theranos, Holmes started dating hotel heir William "Billy" Evans, whom she married in 2019 and with whom she has had two children (born in 2021 and 2023).[10]

In June 2018, a federal grand jury indicted Holmes and Balwani on fraud charges. Her trial in the case of U.S. v. Holmes, et al. ended in January 2022 when Holmes was convicted of defrauding investors and acquitted of defrauding patients.[11] She was sentenced to serve 11+1⁄4 years at Federal Prison Camp, Bryan, beginning on May 30, 2023. She and Balwani were ordered to pay $452 million in restitution to the victims of the fraud. The credibility of Theranos was attributed in part to Holmes's personal connections and ability to recruit the support of influential people, including Henry Kissinger, George Shultz, James Mattis, and Betsy DeVos, all of whom had served or would go on to serve as U.S. presidential cabinet officials.

Early life

[edit]

Elizabeth Anne Holmes was born on February 3, 1984, in Washington, D.C.[12] Her father, Christian Rasmus Holmes IV, was a vice president at Enron, an energy company that later went bankrupt after an accounting fraud scandal. Her mother, Noel Anne (née Daoust), worked as a Congressional committee staffer.[13][12] Christian later held executive positions in government agencies such as USAID, the EPA, and USTDA.[14][15] Holmes is partly of Danish ancestry. One of her paternal great-great-great-grandfathers was Charles Louis Fleischmann, a Jewish-Hungarian immigrant to the United States who founded Fleischmann's Yeast.[16] The Holmes family "was very proud of its yeast empire" history, according to a family friend Joseph Fuisz, "I think the parents very much yearned for the days of yore when the family was one of the richest in America. And I think Elizabeth channeled that, and at a young age."[17]

Holmes graduated from high school at St. John's School in Houston.[18][19] During high school, she was interested in computer programming and says she started her first business selling C++ compilers to Chinese universities.[20] Her parents had arranged Mandarin Chinese home tutoring, and partway through high school, Holmes began attending Stanford University's summer Mandarin program.[21][12] In 2002, Holmes attended Stanford, where she studied chemical engineering and worked as a student researcher and laboratory assistant in the School of Engineering.[13] She was a member of Kappa Alpha Theta at Stanford.[22]

After the end of her freshman year, Holmes worked in a laboratory at the Genome Institute of Singapore and tested for severe acute respiratory syndrome coronavirus (SARS-CoV-1) through the collection of blood samples with syringes.[20][13] She filed her first patent application on a wearable drug-delivery patch in 2003.[23][24] Holmes reported that she was raped at Stanford in 2003.[25] In March 2004, she dropped out of Stanford's School of Engineering and used her tuition money as seed funding for a consumer healthcare technology company.[13][26]

Theranos

[edit]
Main article: Theranos

Founding

[edit]

In 2003, Holmes founded the company Real-Time Cures in Palo Alto, California, to "democratize healthcare".[20][27][28][29] Holmes described her fear of needles as a motivation and sought to perform blood tests using only small amounts of blood.[15][27] When Holmes pitched the idea to reap "vast amounts of data from a few droplets of blood derived from the tip of a finger" to a medicine professor Phyllis Gardner at Stanford, Gardner responded, "I don't think your idea is going to work", explaining it was impossible to do what Holmes was claiming could be done. Several other expert medical professors told Holmes the same thing.[15] However, Holmes did not relent, and she succeeded in getting her advisor and dean at the School of Engineering, Channing Robertson, to back her idea.[15] In 2003, Holmes renamed the company Theranos (a portmanteau of "therapy" and "diagnosis").[30][31] The company's original name was changed after deciding that too many people were skeptical of the word "cure".[32] Robertson became the company's first board member and introduced Holmes to venture capitalists.[13]

Funding and expansion

[edit]

By December 2004, Holmes had raised $6 million to fund the firm.[13] By the end of 2010, Theranos had more than $92 million in venture capital.[23] In July 2011, Holmes was introduced to former secretary of state George Shultz. After a two-hour meeting, he joined the Theranos board of directors.[33] Holmes was recognized for forming "the most illustrious board in U.S. corporate history" over the next three years.[34]

Holmes operated Theranos in "stealth mode" without press releases or a company website until September 2013, when the company announced a partnership with Walgreens to launch in-store blood sample collection centers.[35][36] She was interviewed for Medscape by its editor-in-chief, Eric Topol, who praised her for "this phenomenal rebooting of laboratory medicine".[37] Media attention increased in 2014, when Holmes appeared on the covers of Fortune, Forbes, T: The New York Times Style Magazine, and Inc.[38]

Forbes recognized Holmes as the world's youngest self-made female billionaire and ranked her #110 on the Forbes 400 in 2014.[39] Theranos was valued at $9 billion and had raised more than $400 million in venture capital.[13][40] By the end of 2014, her name appeared on 18 U.S. patents and 66 foreign patents.[24] During 2015, Holmes established agreements with Cleveland Clinic, Capital Blue Cross, and AmeriHealth Caritas to use Theranos technology.[23]

Downfall

[edit]

John Carreyrou of The Wall Street Journal initiated a secret, months-long investigation of Theranos after he received a tip from a medical expert who thought that Theranos's Edison blood testing device seemed suspicious. Carreyrou spoke to ex-employee whistleblowers and obtained company documents. When Holmes learned of the investigation, she initiated a campaign through her lawyer David Boies to stop Carreyrou from publishing, which included legal and financial threats against both the Journal and the whistleblowers.[41][42]

In October 2015, despite Boies's legal threats and strong-arm tactics, the Journal published Carreyrou's "bombshell article"[43] detailing how the Edison device gave inaccurate results, and revealing that the company had been using commercially available machines manufactured by other companies for most of its testing.[44] Carreyrou continued to report problems with the company and Holmes's conduct in a series of articles and, in 2018, published a book titled Bad Blood: Secrets and Lies in a Silicon Valley Startup, detailing his investigation of Theranos.[45][46]

Holmes denied all the claims, calling the Journal a "tabloid" and promising the company would publish data on the accuracy of its tests.[47][48] She appeared on CNBC's Mad Money the same evening the article was published. Jim Cramer said, "The article was pretty brutal", to which Holmes responded, "This is what happens when you work to change things, first they think you're crazy, then they fight you, and then all of a sudden you change the world."[49]

In January 2016, the Centers for Medicare and Medicaid Services (CMS) sent a warning letter to Theranos after an inspection of its Newark, California, laboratory uncovered irregularities with staff proficiency, procedures, and equipment.[50] CMS regulators proposed a two-year ban on Holmes from owning or operating a certified clinical laboratory after the company had not fixed problems in its California lab in March 2016.[51] On The Today Show, Holmes said she was "devastated we did not catch and fix these issues faster" and said the lab would be rebuilt with help from a new scientific and medical advisory board.[52][53]

In July 2016, CMS banned Holmes from owning, operating, or directing a blood-testing service for a period of two years. Theranos appealed that decision to a U.S. Department of Health and Human Services appeals board.[15][54] Shortly thereafter, Walgreens ended its relationship with Theranos and closed its in-store blood collection centers.[55] The U.S. Food and Drug Administration (FDA) also ordered the company to cease use of its Capillary Tube Nanotainer device, one of its core inventions.[56]

In 2017, the State of Arizona filed suit against Theranos, alleging that the company had sold 1.5 million blood tests to Arizonans while concealing or misrepresenting important facts about those tests. In April 2017, the company settled the lawsuit by agreeing to refund the cost of the tests to consumers, and to pay $225,000 in civil fines and attorney fees, for a total of $4.65 million.[57][58] Other reported ongoing actions include an unspecified investigation by the U.S. Federal Bureau of Investigation (FBI) and two class action fraud lawsuits. Holmes denied any wrongdoing.[15]

On May 16, 2017, approximately 99 percent of Theranos shareholders reached an agreement with the company to dismiss all litigation and potential litigation in exchange for shares of preferred stock. Holmes released a portion of her equity to offset any dilution of stock value to non-participating shareholders.[59][60]

In March 2018, the SEC charged Holmes and Theranos's former president, Ramesh Balwani, with fraud by taking more than $700 million from investors while advertising a false product. The charges of fraud included the company's false claim that its technology was being used by the U.S. Department of Defense in combat situations.[61] The company also lied when it claimed to have a $100-million revenue stream in 2014. That year, the company only made $100,000.[62] On March 14, 2018, Holmes settled the lawsuit.[63] The terms of Holmes's settlement included surrendering voting control of Theranos, returning 18.9 million shares to the company, a ban on holding an officer or director position in a public company for 10 years, and a $500,000 fine.[64][65][66]

At its height in 2015, Theranos had more than 800 employees.[67] It dismissed 340 people in October 2016 and an additional 155 in January 2017.[68] In April 2018, Theranos filed a WARN Act notice with the State of California, announcing its plans to permanently lay off 105 employees, leaving it with fewer than two dozen employees.[67][69] Most of the remaining employees were laid off in August 2018. On September 5, 2018, the company announced that it had begun the process of formally dissolving, with its remaining cash and assets to be distributed to its creditors.[70]

U.S. v. Holmes, et al.

[edit]
Main article: United States v. Elizabeth A. Holmes, et al.

On June 15, 2018, after an investigation by the U.S. Attorney's Office for the Northern District of California that lasted more than two years, a federal grand jury indicted Holmes and Balwani on nine counts of wire fraud and two counts of conspiracy to commit wire fraud.[71][72] Both pleaded not guilty. The prosecution alleged that Holmes and Balwani had engaged in two criminal schemes: one to defraud investors, and a second to defraud doctors and patients.[71][73][74] After the indictment was issued, Holmes resigned as CEO of Theranos but remained chairwoman of its board of directors.[72]

Holmes was tried in the U.S. District Court for the Northern District of California, with U.S. district judge Edward Davila presiding. She hired defense lawyers from Williams & Connolly, a prominent American law firm that specializes in white-collar crime defense. The trial began on August 31, 2021,[75] after being delayed for over a year due to the COVID-19 pandemic and Holmes's pregnancy.[76] At trial, Holmes testified on her own behalf for seven days, claiming among other things that she was misled by her staff about the technology, and that Balwani held sway over her during the romantic relationship they had and which was still ongoing when the alleged criminal acts happened.[77][78][79] The case's evidence outlined Holmes's role in faked demonstrations, falsified validation reports, misleading claims about contracts, and overstated financials at Theranos.[2]

On January 3, 2022, the jury found Holmes guilty on four counts of defrauding investors: three counts of wire fraud, and one of conspiracy to commit wire fraud. She was found not guilty on four counts of defrauding patients, and the jury returned a "no verdict" on three counts of wire fraud against investors. The judge declared a mistrial on the last three counts, and the government later agreed to dismiss them.[2][11][80][81] Holmes waited on sentencing while remaining 'at liberty' on $500,000 bail, secured with property.[82][83] She faced a maximum sentence of 20 years in prison, and a fine of $250,000, plus restitution, for each count of wire fraud and for each conspiracy count.[75][2]

On November 18, 2022, Davila sentenced Holmes to 11+1⁄4 years in federal prison and ordered her and Balwani jointly to pay $452 million in restitution to the victims of the fraud.[84][1] He recommended she be incarcerated at Federal Prison Camp, Bryan, a minimum-security federal prison in Bryan, Texas. On May 17, 2023, Davila ruled that she must surrender to custody on May 30, after accepting that she needed time to arrange childcare for her two children.[85] Holmes reported to prison on May 30.[86] In July 2023, the Bureau of Prisons projected that Holmes would be released from prison in 2032, approximately two years early, in accordance with the Bureau's guidelines for good conduct time.[87][88]

Holmes appealed her conviction and sentence to the U.S. Court of Appeals for the Ninth Circuit. Her lawyers argued that Davila had committed legal errors by, among other things, allowing the prosecution to introduce certain government reports and expert witness analysis, by restricting their cross-examination of former Theranos laboratory director Adam Rosendorff, and by excluding some of Balwani's testimony. A panel consisting of U.S. circuit judges Jacqueline Nguyen, Ryan D. Nelson, and Mary M. Schroeder heard oral argument in her case in June 2024.[89] In February 2025, the Ninth Circuit rejected Holmes' arguments and affirmed her conviction and sentence.[90]

Promotional activities

[edit]

Holmes partnered with Carlos Slim in June 2015 to improve blood testing in Mexico.[91] In October 2015, she announced #IronSisters to help women in science, technology, engineering, and mathematics careers.[92] In 2015, she helped to draft and pass a law in Arizona to let people obtain and pay for lab tests without requiring insurance or healthcare provider approval, while misrepresenting the accuracy and effectiveness of the Theranos device.[93][94]

Connections

[edit]

Theranos's board and investors included many influential figures.[95][96] Holmes's first major investor was Tim Draper – Silicon Valley venture capitalist and father of Holmes's childhood friend Jesse Draper – who "cut Holmes a check" for $1 million upon hearing her initial pitch for the firm that would become Theranos.[97][98] Theranos's pool of major investors expanded to include[96] Rupert Murdoch, the Walton family, the DeVos family including Betsy DeVos, the Cox family of Cox Enterprises and Carlos Slim Helú. Each of these investors lost tens to hundreds of millions of dollars when Theranos folded.[96]

One of Holmes's first board members was George Shultz.[99][97] With Shultz's early involvement aiding Holmes's recruitment efforts, the 12-member Theranos board eventually included:[100] Henry Kissinger, a former secretary of state; William Perry, a former secretary of defense; James Mattis, a future secretary of defense; Gary Roughead, a retired U.S. Navy admiral; Bill Frist, a former U.S. senator (R-TN); Sam Nunn, a former U.S. senator (D-GA); and former CEOs Dick Kovacevich of Wells Fargo and Riley Bechtel of Bechtel.[101][102]

Recognition and public image

[edit]

Before the collapse of Theranos, Holmes received widespread acclaim. In 2015, she was appointed a member of the Harvard Medical School Board of Fellows[103] and was named one of Time magazine's "Time 100 most influential people".[104] Holmes received the Under 30 Doers Award from Forbes and was ranked number 73 in its 2015 list of "the world's most powerful women".[105][106] She was also named Woman of the Year by Glamour and received an Honorary Doctor of Humane Letters from Pepperdine University.[107][108]

Holmes was awarded the 2015 Horatio Alger Award of the Horatio Alger Association of Distinguished Americans, making her its youngest recipient in history.[30][109] She previously had been named Fortune's Businessperson of the Year and had been listed in its 40 Under 40 feature.[110][111] In 2015, she was a member of Bloomberg's 50 Most Influential.[112] In the same year actor Jared Leto presented her with a Glamour Award[113] and then-US President Barack Obama named her as Presidential Ambassador for Global Entrepreneurship.[114] In 2016, Fortune named Holmes in its article on "The World's 19 Most Disappointing Leaders".[7]

Holmes was an admirer of Apple founder Steve Jobs, and deliberately copied his style, frequently dressing in a black turtleneck sweater, as Jobs did.[115] Holmes said her mother dressed her in black turtlenecks when she was young[116] and that she had worn the turtlenecks beginning around the age of eight,[117] but she also claims that she started wearing black turtlenecks upon founding the company in 2003.[118] An employee said she suggested Holmes copy Jobs's famous Issey Miyake turtleneck look in 2007.[119]

During most of her public appearances, she spoke in a deep baritone voice, although a former Theranos colleague later claimed he heard her speak in a voice stereotypical of a woman her age to welcome him when he was hired.[120][121] Gardner of Stanford also denies that Holmes has a naturally deep voice.[122] Her family, however, has maintained that her deep voice is authentic.[123][124] In a 2023 New York Times interview, Holmes spoke in her natural, higher pitch voice, and confirmed that the low voice was an affectation.[125]

Personal life

[edit]
Holmes at Stanford University, 2013

Holmes was romantically involved with the Pakistani-born technology entrepreneur Ramesh "Sunny" Balwani, who immigrated to India and then the US.[126][127] She met him in 2002 during a trip to Beijing as part of Stanford University's Mandarin program. Holmes was 18 at the time and had just graduated from high school; Balwani is 19 years older than Holmes and he was married to another woman at the time.[9][128]

Balwani divorced his wife in 2002[129] and became romantically involved with Holmes in 2003, about the same time Holmes dropped out of university.[9] The couple moved into an apartment together in 2005. Although Balwani did not officially join Theranos until 2009, when he was given the title of chief operating officer, he was advising Holmes behind the scenes from the company's inception.[9] Balwani left Theranos in 2016 in the wake of investigations. The circumstances of his departure are unclear; Holmes has stated that she fired him, but Balwani says that he left of his own accord.[9]

On November 29, 2021, Holmes testified that she had been raped while she was a student at Stanford and that she sought solace from Balwani in the aftermath of the incident.[77][78] She also said Balwani was very controlling during their romantic relationship, which lasted more than a decade, and at times he berated and sexually abused her.[77][78] In her testimony, she stated he also wanted to "kill the person" she was and create a "new Elizabeth".[77] However, she also testified that Balwani had not forced her to make the false statements to investors, business partners, journalists and company directors that had been described in the case.[130] In court filings, Balwani has "categorically" denied abuse allegations, calling them "false and inflammatory."[131]

Before the March 2018 settlement, Holmes owned half of Theranos's stock.[20] Forbes listed her as one of U.S. Richest Self-Made Women in 2015 with a net worth of $4.5 billion.[40] In June 2016, Forbes released an updated valuation of $800 million for Theranos, which made Holmes's stake essentially worthless, because other investors owned preferred shares and would have been paid before Holmes, who owned only common stock.[6] Holmes reportedly owed a $25 million debt to Theranos in connection with exercising stock options. She did not receive any company cash from the arrangement, nor did she sell any of her shares, including those associated with the debt.[132][133][134]

Holmes first met William "Billy" Evans in early 2017.[135] In early 2019, Holmes became engaged to Evans, a 27-year-old heir to Evans Hotels, a family-owned group of hotels in the San Diego area.[136][135] In mid-2019, Holmes and Evans reportedly married in a private ceremony.[137][138] Holmes and Evans have not directly confirmed whether the two are legally married, and several sources continue to refer to him as her "partner" rather than her husband.[139][140] Holmes gave birth to a son in July 2021.[140] In October 2022, weeks before her sentencing hearing, it was reported she was pregnant with a second child.[141] Holmes was accused of conceiving a second child, according to a court filing from February 2023, as a strategy for delaying the start of her prison term.[142] Holmes denied this, saying she wanted to grow her family and the child was conceived before she was indicted, which she did not anticipate.[135] Prior to her incarceration, she lived in the Mortimer Fleishhacker House in Woodside, California, with her partner.[143][144]

In January 2022, NPR obtained a copy of a partial police report from the evening of October 5, 2003, in which Holmes called the police and alleged she had been sexually assaulted at a fraternity house at Stanford between 1 a.m. and 3 a.m. that morning. The police report supported claims made by Holmes during the trial, in which she said: "I was questioning how I was going to be able to process that [rape] experience and what I wanted to do with my life, and I decided that I was going to build a life by building [a company]." She had started Theranos later that year. The report, written by the deputies who responded to the call, was withheld from release, and the partial information obtained by NPR does not identify an alleged perpetrator or other details about the incident but identifies the street address of the Sigma Chi fraternity house as the location.[145]

In the media

[edit]

The case of Holmes is said to have created a stigma for other female entrepreneurs, particularly in the sciences and health care industries, who are often compared to her. Writing in The New York Times, technology journalist Erin Griffith commented that "Holmes continues to loom large across the start-up world because of the audacity of her story, which has permeated popular culture", with female entrepreneurs reporting that "the frequent comparisons [to Holmes] are pernicious".[146] Holmes has also been featured in a number of media works:[147]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Elizabeth Holmes

View on Grokipedia
from Grokipedia
Elizabeth Holmes (born February 3, 1984) is an American businesswoman and convicted felon who founded the blood-testing startup in 2003 after dropping out of . Theranos claimed to have invented a proprietary device, the Edison, capable of running hundreds of diagnostic tests from a single drop of blood using minimal resources, a technology that purportedly disrupted traditional laboratory methods but was later proven ineffective and largely nonexistent. The company's assertions attracted approximately $900 million in from prominent investors, briefly elevating Holmes to billionaire status and Theranos to a $9 billion valuation, though these figures rested on demonstrably false demonstrations and suppressed evidence of technological shortcomings. Revelations beginning in 2015 exposed systemic deception, including the use of unmodified commercial analyzers for most tests and fabrication of validation data, culminating in regulatory sanctions, the firm's dissolution in 2018, and Holmes's indictment for . In January 2022, she was convicted on four felony counts of and wire related to defrauding investors of hundreds of millions of dollars; she was acquitted on charges involving patient deception. Holmes received a sentence of 135 months in in 2022 and began serving it in 2023 at a minimum-security facility in , where she remains as of 2025 following the denial of her appeals.

Early Life and Education

Family Background and Childhood

Elizabeth Holmes was born on February 3, 1984, in , to Christian Holmes IV and Noel Anne Holmes. Her father, a descendant of the Fleischmann family associated with the yeast industry fortune, held positions in U.S. government agencies including the United States Agency for International Development (USAID) and the State Department before becoming a at in the 1990s. Her mother worked as a foreign policy and defense aide on , including under figures like , prior to focusing on raising the family. The family lived comfortably in a politically oriented household, with Christian's international roles influencing frequent relocations; they moved to , , around 1994 when he joined , exposing Holmes to environments tied to her father's career in and . Holmes has one brother, Christian Holmes V, who later worked at her company . Her parents supported her early ambitions, drawing from Christian's experiences in humanitarian and governmental work abroad. As a child, Holmes was described by acquaintances as polite yet withdrawn and private, displaying determination in pursuits despite challenges, such as in school activities where she persisted even when finishing last. The family's moves, including time in , shaped a childhood marked by adaptability amid her father's professional shifts, though specific personal anecdotes from this period remain limited in public accounts.

Formal Education and Early Interests

Holmes attended St. John's School, a private institution in , , graduating in 2002. During high school, she cultivated a rigorous by studying late into the night and maintained straight-A grades. Her early entrepreneurial inclinations emerged through an interest in , prompting her to launch a selling C++ coding software to students at Chinese schools. Following her sophomore year, Holmes persuaded to admit her to college-level language courses, reflecting an emerging fascination with Mandarin and international opportunities in . In the fall of 2002, Holmes enrolled at as a chemical engineering major. She demonstrated academic promise in her initial semesters but grew increasingly focused on innovations, particularly ideas for portable medical diagnostics inspired by her aversion to traditional blood draws. By her sophomore year, Holmes had begun prototyping early inventions, including a wearable patch for , which aligned with her high school-era habit of sketching inventions and patents. In March 2004, at age 19, Holmes withdrew from to devote herself fully to developing her blood-testing technology startup, redirecting her tuition funds as seed capital. This decision stemmed from her conviction that formal coursework hindered rapid progress on what she viewed as a transformative health innovation, though it later drew scrutiny for prioritizing unproven ideas over completed engineering training.

Founding and Development of Theranos

Inception of the Idea

Elizabeth Holmes, born on February 3, 1984, enrolled at in the fall of 2002 as a major. During her freshman year, in 2003, she conceived the core idea for what would become : a compact device capable of conducting hundreds of diagnostic blood tests using minimal volumes of blood, such as a single drop from a finger prick, to reduce the need for traditional . This concept was motivated by Holmes's personal aversion to needles, which she described as a "traumatic ," stemming from her own experiences and observations of members undergoing blood draws. The initial prototype envisioned by Holmes was a wristwatch-like patch applied to the arm, designed to scan for infectious diseases via microscopic blood samples or sweat analysis and potentially deliver antibiotics directly if pathogens were detected. Holmes pitched this idea to Stanford pharmacology professor Phyllis Gardner shortly after arriving on campus in 2002, but Gardner rejected it as scientifically implausible, citing biological impossibilities in detecting and treating conditions through such a mechanism without larger blood volumes or established drug-delivery methods. Undeterred, Holmes approached chemical engineering professor Channing Robertson, who found the proposal compelling enough to provide guidance and later join as Theranos's first board member. In late 2003, at age 19, Holmes incorporated the venture as Real-Time Cures, funded initially with approximately $6,000 from her college tuition savings, aiming to "democratize" lab testing by making it faster, cheaper, and less invasive. The company name was soon changed to , a portmanteau of "" and "," reflecting the dual focus on detection and potential treatment. This marked the shift from academic concept to entrepreneurial pursuit, though early , such as Gardner's, highlighted foundational challenges in the proposed technology's feasibility from microfluidic to detection limits.

Initial Technological Claims and Prototypes

In 2003, Elizabeth Holmes, then 19 years old and a freshman at , conceived the idea for a wearable patch or device that could analyze microscopic volumes of blood for multiple diseases, motivated by her personal aversion to traditional blood draws. She incorporated later that year, dropping out of Stanford to pursue the technology full-time, with initial claims centering on a portable analyzer capable of conducting up to 240 blood tests—ranging from basic metabolic panels to complex assays for conditions like cancer and —using only a finger-prick drop of blood (approximately 0.1 milliliter), delivering results in hours rather than days. These assertions positioned the technology as a disruptive alternative to conventional lab analyzers, which typically required samples of several milliliters per test and centralized processing. The company's first prototype, designated Theranos 1.0, emerged in 2005 as a cartridge-based reader system intended to process small volumes through microfluidic channels for and other diagnostic reactions. By this point, Theranos had grown to over 24 employees and secured early patents related to sample handling, though the prototype's functionality remained under development and unvalidated for the full scope of claimed tests. In September 2007, introduced an updated prototype called the Edison, a tabletop-sized unit adapted from a commercial glue-dispensing , equipped with a small to automate mixing, incubation, and detection processes for immunoassays on diluted finger-prick samples. Holmes named the device after inventor and promoted it as capable of handling over 200 tests with high accuracy from sub-microliter volumes, emphasizing its potential for point-of-care use in clinics, pharmacies, or homes to enable rapid, decentralized diagnostics. Early demonstrations and internal testing focused on a limited subset of assays, such as those for , but the prototypes required manual interventions and showed inconsistencies in , prompting iterative refinements amid growing company valuation exceeding $200 million by late 2007.

Theranos Operations and Growth

Fundraising and Investor Relations

Theranos, founded by Elizabeth Holmes in , initially relied on modest seed funding from personal networks before attracting . By 2010, the company raised $45 million in a funding round that valued it at $1 billion, marking its entry into status. This early success stemmed from Holmes' pitches emphasizing revolutionary blood-testing technology, though investors received limited access to operational details due to strict nondisclosure agreements (NDAs) that restricted independent verification. Subsequent rounds accelerated amid growing hype. By December 2014, had secured over $400 million cumulatively from venture capitalists and private investors, with valuations climbing toward $9 billion at peak. Between 2014 and 2015 alone, investors committed $632 million, including high-profile figures such as Rupert Murdoch's family ($100 million), the DeVos family, and media heirs from the Cox and Walton families. Overall, the company amassed approximately $1.3 billion in equity funding (excluding debt), drawn by promises of disruptive diagnostics but often based on controlled demonstrations of devices rather than scalable, validated . Holmes maintained investor relations through a combination of , secrecy, and celebrity endorsements. She assembled a board dominated by prominent non-experts, including former U.S. Secretaries of State and , retired General James Mattis, and Stanford professor , whose prestige lent unmerited scientific credibility without demanding rigorous technical oversight. NDAs and "" demos—where devices were prepped in ways not replicable in routine use—shielded underlying limitations, fostering trust among investors who prioritized Holmes' vision over empirical validation. These practices later drew scrutiny in Holmes' 2022 criminal trial, where evidence showed misrepresentations, such as 2010 projections to investors of $223 million in revenue despite internal knowledge of infeasibility. Investors, including sophisticated parties, overlooked red flags like the absence of peer-reviewed or third-party audits, attributing the company's opacity to rather than potential . This dynamic highlighted vulnerabilities in Silicon Valley's high-stakes fundraising ecosystem, where narrative often outpaced due diligence.

Partnerships and Commercial Expansion

In September 2010, Theranos contracted with , referred to as "Grocery A" in regulatory filings, to integrate its blood-testing services into stores as part of a project code-named "T-Rex." The agreement, initiated around 2011, involved investing approximately $350 million to $400 million in remodeling store pharmacies and wellness centers to accommodate Theranos' finger-prick testing devices, aiming to provide on-site diagnostic services to customers. conducted extensive , estimated at over 100 hours by former CEO Steven Burd, before committing to the exclusive retail , which sought to expand access to rapid blood tests without traditional . The collaboration remained undisclosed publicly until 2015, when terminated it amid operational failures, having built infrastructure in hundreds of stores across chains like , , and . Theranos announced a public partnership with Walgreens on September 9, 2013, selecting it as a long-term collaborator to roll out clinical laboratory services in retail settings, beginning with a pilot in 40 locations. Walgreens invested $140 million in to support this expansion, envisioning in-store kiosks for finger-stick blood tests that would deliver results to patients' mobile devices, bypassing conventional labs. Elizabeth Holmes had pitched the concept of deploying devices in pharmacies as early as 2010, targeting major chains to enable immediate, and disrupt the $75 billion U.S. lab diagnostics market through retail accessibility. The Walgreens deal marked ' primary commercial launch, with plans to scale nationwide, though validation of the proprietary Edison device was limited to internal demos rather than independent verification prior to rollout. These retail alliances fueled Theranos' growth narrative, attracting further investor interest and elevating its valuation to $9 billion by 2014, as partnerships signaled viable market penetration for miniaturized testing. However, execution stalled due to unproven technology, leading to reliance on third-party labs for most tests while marketing claimed proprietary capabilities, a discrepancy later central to fraud allegations. Walgreens ultimately settled customer lawsuits for $44 million in 2023 over inaccurate results from the partnership.

Internal Operations and Employee Experiences

Theranos maintained a highly secretive internal environment, where employees were required to sign stringent non-disclosure agreements (NDAs) that restricted discussions of the company's technology, even among staff working on compartmentalized projects. This structure limited cross-team knowledge sharing, fostering isolation and preventing comprehensive evaluation of the Edison device's performance issues. Former employees reported that questioning the technology's viability often led to swift termination, as viewed as disloyalty rather than constructive feedback. Sunny Balwani, Theranos' president and chief operating officer, enforced a management style characterized by intimidation and rapid firings of employees who raised concerns about testing accuracy or regulatory compliance. In one instance, a microbiologist advocating for industry-standard protocols was dismissed after challenging Balwani's directives. Balwani's emails to staff who doubted the blood-testing results were harshly critical, accusing them of undermining the mission and demanding unquestioning adherence to ambitious timelines. Elizabeth Holmes, while projecting a charismatic vision to external stakeholders, was described by insiders as aloof internally, rarely engaging directly with operational challenges and deferring day-to-day enforcement to Balwani. Employee experiences were marked by a pervasive , where hinged on avoiding scrutiny of the technology's flaws, leading to ethical dilemmas for scientifically trained staff. Departing employees faced aggressive NDA enforcement; in at least one case, security personnel were instructed to physically prevent an individual from leaving the premises until signing the agreement. This atmosphere contrasted with superficial perks like free gourmet meals and wellness programs, which masked underlying dysfunction, including impossible deadlines for validating proprietary assays that repeatedly failed quality controls. By 2015, as internal plummeted amid voided test results, the company's retention of talent relied on oaths and isolation tactics rather than transparent problem-solving.

Technological Reality and Deception

Device Capabilities and Testing Failures

Theranos promoted its proprietary Edison device as capable of conducting up to 240 clinical laboratory tests from volumes of blood as small as a finger prick, utilizing microfluidic technology and custom cartridge-based assays to detect conditions ranging from infectious diseases to cancer markers. In practice, however, the device demonstrated limited functionality, reliably performing only a handful of basic tests such as those for glucose and under controlled conditions, while struggling with the required sample volumes and assay precision for more complex analyses. Internal validation efforts revealed that the Edison often required dilution of blood samples to reach viable volumes, undermining claims of minimal invasiveness, and it failed to achieve consistent across runs. Quality control testing for the Edison routinely failed, with error rates exceeding acceptable thresholds in both research and clinical settings; for instance, former lab associate Erika Cheung testified during the 2021 trial that machines produced results with wide variations on patient samples, prompting the use of ad hoc methods like "outlier deletion" to discard discrepant data and artificially improve reported performance metrics. A Wall Street Journal investigation, corroborated by internal documents, found that the devices frequently missed the company's own accuracy specifications for tests including , sodium, and chloride, with failure instances documented as early as 2014 during preparations for commercial rollout. Trial evidence highlighted specific assay shortcomings, such as inaccuracy rates of approximately 30% for tests and over 50% failure rates for assays prior to the partnership in 2013, leading to inconsistent diagnostic outputs that risked patient harm. inspections in 2015 identified failures in ensuring for the proprietary system, including unvalidated protocols that contributed to erroneous results in an estimated one in ten tests overall. Demonstrations of the device to investors and partners were selectively managed to conceal these issues, with software modifications employed to suppress error messages and halt processes upon detection of failures. Ultimately, these technical deficiencies prompted to route the majority of commercial tests through modified third-party analyzers rather than the Edison, contradicting public representations of self-sufficient innovation.

Data Manipulation and False Reporting

Theranos laboratory personnel routinely manipulated data from its proprietary Edison devices by excluding results that indicated failures or inaccuracies, thereby fabricating reports that overstated the technology's reliability. Whistleblower Erika Cheung, a former lab associate, testified during the 2021 trial that such data alterations occurred frequently to align validation reports with desired outcomes for investor scrutiny, including the selective deletion of runs showing inconsistencies. Internal emails presented as revealed directives to hide device malfunctions and remove abnormal results from aggregated reports, ensuring presentations to partners like portrayed consistent accuracy where none existed. For instance, proficiency testing required for was falsified by routing samples to commercial analyzers from rather than the Edison, with results then attributed to technology; Holmes approved modifications to these third-party machines to fit smaller blood volumes, despite knowing they produced unreliable outputs. These practices extended to patient outcomes, where the Edison generated erroneous results in approximately 10% of tests, including false positives for and , and false negatives for conditions like and cancer, leading to misdiagnoses without disclosure. Trial evidence confirmed Holmes was aware of these discrepancies, as internal documents showed the analyzer failed to meet basic accuracy standards for over a dozen assays, yet reports to investors claimed validation against pharmaceutical benchmarks using cherry-picked data subsets. Demonstrations for stakeholders involved pre-arranged blood dilutions or rigged samples to simulate success, with failed runs omitted from records; one such instance involved altering proficiency test submissions in 2014 to evade detection by regulators. This systematic falsification contributed to the deception of over 1 million tests conducted from 2013 to 2015, primarily via modified commercial equipment misrepresented as proprietary innovation.

Scientific and Regulatory Violations

Theranos' proprietary Edison device failed to meet the company's internal accuracy requirements for numerous blood tests, with internal data showing error rates exceeding acceptable thresholds in proficiency testing and assessments conducted between 2013 and 2015. These failures included inconsistent results for analytes such as , sodium, and , where the device produced readings that deviated significantly from reference standards, rendering the tests unreliable for clinical use. Validation processes were inadequate, lacking rigorous, peer-reviewed studies to confirm the device's performance across the claimed 200+ tests from finger-prick samples, as required under standard laboratory protocols; instead, Theranos relied on limited, non-representative data sets that omitted failed runs. An FDA inspection of ' Newark, California facility in September 2015 uncovered multiple violations of the Federal Food, Drug, and Cosmetic Act, including 13 objectionable conditions such as inadequate process controls, failure to investigate device malfunctions, and insufficient complaint handling procedures. The agency classified the Theranos nanotainer as a Class II requiring premarket notification, which Theranos had not obtained, and issued a warning letter in 2016 prohibiting distribution of certain tests due to unapproved status and quality system deficiencies. Theranos exploited regulatory gaps by classifying its technology as a laboratory-developed test (LDT) to bypass full FDA premarket review, despite promoting it as a novel diagnostic platform, which delayed scrutiny but ultimately exposed non-compliance with good laboratory practices. Under the (CLIA), the (CMS) surveyed ' laboratory in early 2016 and cited violations of five condition-level requirements, including deficient recordkeeping, absence of quality audits, and improper validation of an unnamed testing device to ensure conformity to established specifications. CMS imposed sanctions revoking the laboratory's CLIA certification effective September 2016, barring from operating as a clinical lab, and prohibiting Elizabeth Holmes, along with executives Balwani and Sunil Dhawan, from owning or operating a CLIA-certified lab for two years. These regulatory breaches stemmed from systemic issues, including the secret routing of patient samples to third-party commercial analyzers like those from , contradicting claims of proprietary technology, which violated CLIA mandates for accurate proficiency testing and result reporting.

Investigations and Downfall

Whistleblower Actions

Tyler Shultz, a at from 2013 to April 2014 and grandson of board member , internally raised concerns about the inaccuracy of the company's Edison device, including the undisclosed dilution of small blood samples from finger pricks to run on third-party analyzers, which compromised result reliability. After resigning, Shultz contacted Journal reporter in late 2015 using a burner phone, providing internal emails—including exchanges with Elizabeth Holmes—and documents detailing testing failures and deceptive practices, which contributed to the paper's October 2015 exposé on . responded by issuing a cease-and-desist letter in November 2015 and filing a against Shultz for alleged breach of confidentiality, leading to a protracted legal defense supported by counsel and straining family ties with his grandfather; the suit was eventually dropped amid mounting scrutiny. Shultz later testified as a key prosecution witness in Holmes' 2021 criminal trial, recounting efforts to alert senior leadership that were dismissed. Erika Cheung, a lab associate at Theranos from 2013 to August 2014, documented repeated failures in the Edison machines, such as erroneous readings and unreported discrepancies between device outputs and manual validations, which risked harm. After internal reports to supervisors and attempts to escalate to the board were ignored, Cheung provided Carreyrou with evidence of manipulated proficiency testing and hidden errors, aiding the WSJ's reporting that prompted regulatory probes. Like Shultz, she faced legal threats from Theranos aimed at silencing disclosure before the story broke. Cheung testified in Holmes' on September 15, 2021, detailing specific instances where Theranos overrode machine error alerts to release invalid results. The whistleblowers' disclosures to Carreyrou were pivotal in unraveling ' claims, as prior internal complaints had yielded no reforms, and their cooperation bypassed company suppression tactics, ultimately fueling CMS and SEC investigations starting in 2015. No other employees emerged as public whistleblowers of comparable impact, though anonymous tips had earlier alerted regulators like the FDA.

Journalistic Exposés and Regulatory Probes

In October 2015, Journal reporter published a series of investigative articles exposing significant flaws in ' blood-testing technology, revealing that the company was not conducting most of its advertised tests using its Edison device but instead relied on modified commercial analyzers from third parties, with results often inaccurate or unreliable. The reporting, based on interviews with former employees and internal documents, detailed how Theranos had overstated the device's capabilities, claiming it could perform hundreds of tests from a single drop of blood while hiding validation failures and employee concerns about . Carreyrou's work, which began after tips from whistleblowers, prompted Theranos to issue rebuttals and threaten legal action against him and sources, but subsequent articles in 2015 and 2016 further uncovered a culture of secrecy, including non-disclosure agreements stifling dissent and falsified demonstrations to investors and partners. The journalistic scrutiny triggered regulatory investigations, starting with U.S. (FDA) inspections of facilities in , and , in August and September 2015, which resulted in Form 483 observations citing 14 deficiencies, including the use of an unapproved Class II medical device—the nanotainer blood collection tube—and inadequate processes that failed to ensure accurate test results or handle customer complaints. In response, the FDA issued a warning letter and ordered to cease using the nanotainer, while also highlighting broader issues like undocumented audits and unvalidated device modifications, which violated federal regulations under the (CLIA). Further probes by the Securities and Exchange Commission (SEC) culminated in civil charges on March 14, 2018, accusing Elizabeth Holmes and former president Ramesh "Sunny" Balwani of orchestrating an "elaborate, years-long " by misleading investors about the technology's efficacy, leading to over $700 million raised under false pretenses; Holmes agreed to relinquish control of the company, pay a $500,000 penalty, and face a 10-year bar from serving as an officer or director of a . Paralleling this, the U.S. Department of Justice (DOJ) secured a on June 14, 2018, charging Holmes and Balwani with 11 counts of wire and for defrauding investors, doctors, and patients through false claims about test accuracy and speed, with the investigation involving the FBI, FDA Office of Criminal Investigations, and U.S. Postal Inspection Service. These actions exposed systemic violations, including the dilution of patient samples and secret outsourcing of tests, confirming the deceptions highlighted in earlier reporting.

Company Collapse and Leadership Changes

In the wake of regulatory scrutiny and journalistic revelations in 2015, faced escalating operational restrictions that precipitated its contraction. On January 25, 2016, the U.S. (FDA) issued a warning letter to Theranos citing issues in its blood-testing processes, followed by a ban on the company's proprietary Edison device for diagnostic use. Subsequently, on July 7, 2016, the (CMS) revoked Theranos's clinical and imposed a two-year ban on Holmes and COO Ramesh "Sunny" Balwani from owning or operating any clinical lab receiving federal reimbursements, effectively halting most testing operations. These measures, combined with the withdrawal of partnerships like , forced Theranos to refund customers and abandon its retail model. By October 5, 2016, announced the closure of its clinical laboratories in and , as well as its Wellness Centers inside stores, resulting in the of approximately 340 employees—about 40% of its workforce at the time. The company shifted focus to , but with severely diminished revenue—previously reliant on testing services—and mounting legal costs, it struggled to sustain operations. Investors, including Partner Fund Management, pursued and settlements, recovering partial funds but highlighting the firm's inability to pivot or attract buyers. Leadership transitions accelerated amid federal investigations. On March 14, 2018, the U.S. Securities and Exchange Commission (SEC) charged Holmes and Balwani with massive for inflating Theranos's technology capabilities to raise over $700 million from investors; Holmes settled by paying a $500,000 penalty, returning 18.9 million shares, and relinquishing voting control, though she initially retained her board chair role. On June 15, 2018—the same day criminal indictments against Holmes and Balwani were unsealed—Holmes stepped down as CEO, with David Taylor appointed as interim CEO to oversee wind-down efforts; she remained executive chairwoman. Balwani, who had effectively exited operational roles earlier amid internal probes, faced similar restrictions but no formal CEO transition was announced for him. Theranos formally ceased operations on September 4, 2018, notifying investors it would dissolve, liquidate assets, and distribute remaining cash—estimated at around $1 million after debts—to creditors, as no acquisition materialized despite exploratory efforts. The dissolution process, overseen by the board, extended into 2019, marking the end of the company Holmes founded in 2003. These events underscored the causal link between unverifiable technological claims and unsustainable business practices, as prior secrecy and regulatory non-compliance eroded stakeholder trust beyond recovery.

Criminal Charges and Trial

In June 2018, a federal in the Northern District of California indicted Elizabeth Holmes and Ramesh "Sunny" Balwani on eleven felony counts consisting of nine counts of wire fraud and two counts of conspiracy to commit wire fraud. The alleged that, from at least 2010 through 2015, Holmes and Balwani knowingly and willfully conspired to defraud investors, partners, and patients by making material misrepresentations about the capabilities and reliability of 's blood-testing technology, including claims that its Edison device could perform hundreds of tests from small blood samples with accuracy comparable to conventional lab methods. Prosecutors asserted that these false statements, transmitted via wire communications across state lines, induced investors to provide over $700 million to the company and led to launch in-store testing centers using devices that produced unreliable results. A superseding issued in July 2019 expanded the charges to explicitly include four counts related to defrauding patients who received inaccurate test results, such as erroneous diagnoses that prompted unnecessary treatments or delayed care. Holmes was arraigned in July 2018, released on $500,000 bond with conditions including passport surrender and travel restrictions, and entered a not guilty plea, with her defense arguing that optimistic projections about the technology were not fraudulent intent but genuine belief in its potential despite setbacks. Pre-trial proceedings faced multiple delays, including from the , Holmes's pregnancy and childbirth in August 2021, and disputes over evidence admissibility, such as the defense's attempt to introduce a "mental " or abuse-by-Balwani claim, which was partially allowed but limited. The cases against Holmes and Balwani were severed in 2020 at the defense's request to avoid from Balwani's domestic partner allegations against Holmes. Holmes's trial commenced with on August 31, 2021, in U.S. District in , before Judge , followed by opening statements on September 8, 2021. Over 15 weeks, prosecutors presented evidence from 29 witnesses, including former employees who testified to internal knowledge of device inaccuracies, such as dilution of samples for commercial tests routed to third-party labs, and investors like who described reliance on Holmes's representations. The defense called ten witnesses, with Holmes testifying for seven days in December 2021, claiming she was misled by unnamed colleagues (later implied to include Balwani) about the technology's viability and that she held a good-faith belief in its promise, while invoking her right against on certain investor-specific questions. Closing arguments in late December highlighted disputes over intent, with prosecutors emphasizing Holmes's override of scientific concerns and the defense portraying her actions as ambitious innovation amid regulatory hurdles rather than deliberate deceit. The of eight men and four women deliberated for seven days starting December 23, 2021, initially deadlocking on the patient-related counts, which were later dismissed by . On January 3, , they returned a split , convicting Holmes on four counts: one to commit wire against investors and three wire counts tied to specific transmissions misleading investors about the technology's deployment in military use and proficiency testing. She was acquitted on four investor- counts and the deadlocked on three patient- counts, leading to a mistrial on those, which prosecutors chose not to retry.

Convictions, Sentencing, and Initial Incarceration

On January 3, 2022, a federal in , convicted Holmes of four felony counts related to defrauding investors: one count of to commit wire and three counts of wire . She was acquitted on four counts involving defrauding patients, with the deadlocking on three other patient-related wire charges. On November 18, 2022, U.S. District sentenced Holmes to 135 months (11 years and three months) in , followed by three years of supervised release, for her role in the multimillion-dollar investor fraud scheme. The court also ordered Holmes and former Theranos executive Ramesh "Sunny" Balwani to pay $452 million in restitution jointly and severally to victims, including investors and pharmacies, reflecting the scheme's estimated $452 million loss to defrauded parties. Davila emphasized the sentence's intent to promote respect for the law and deter similar corporate deceptions, noting Holmes's lack of remorse during sentencing. Holmes remained free on bond pending appeals, with an initial reporting date of April 27, 2023, later extended to , 2023, following a request to care for her newborn child. On , 2023, she self-surrendered to the Federal Prison Camp (FPC) Bryan, a low-security women's facility in , designated by the Bureau of Prisons for her incarceration. Initial Bureau of Prisons projections set her release for December 29, 2034, accounting for good time credits, though subsequent adjustments under sentencing reforms shortened this to December 2032 and later August 2032.

Appeals Process and Outcomes

Holmes filed a notice of appeal on April 12, 2023, challenging her January 2022 conviction on four counts of wire fraud and her November 18, 2022, sentence of 135 months imprisonment, plus three years supervised release and $452 million in restitution. Key arguments included claims of evidentiary errors by U.S. District Judge , such as restrictions preventing her from referencing Ramesh "Sunny" Balwani's testimony during her defense, and assertions that the jury instructions inadequately addressed her reliance on Balwani's purported misconduct. On February 24, 2025, a three-judge panel of the U.S. Court of Appeals for the Ninth Circuit unanimously affirmed Holmes's convictions, sentence, and restitution order, rejecting her challenges to the evidentiary rulings and as lacking merit. The panel also upheld the parallel convictions and sentence of Balwani, her former business partner and co-defendant, on 12 counts of , finding no abuse of discretion by the district court. Holmes petitioned for a rehearing en banc before the full Ninth Circuit, which was denied unanimously on May 8, 2025, closing off further review at that level and solidifying the affirmation of her guilt on the investor fraud counts. As of October 2025, no petition for certiorari to the U.S. has been granted, leaving her conviction and 11-year-plus term intact while she serves at in . The rulings emphasized the sufficiency of showing Holmes's knowing participation in false representations to investors about Theranos's blood-testing .

Post-Conviction Developments (2023–2025)

Holmes reported to , a low-security facility in , on May 30, 2023, to begin serving her 135-month sentence for wire fraud and conspiracy to commit wire fraud, following a delay granted due to the recent birth of her second child. Assigned inmate number 24965-111, she has participated in rehabilitative programs and worked as a reentry clerk and legal aide, earning credits under the that reduced her projected release date. In May 2024, the adjusted Holmes's release date to August 29, 2032, reflecting approximately two years of reductions from good conduct and program participation, down from an initial projection near December 2034. By June 2025, she filed a motion seeking an additional 27-month reduction, arguing her and rehabilitation efforts demonstrated sufficient remorse and reform to warrant or sentence modification under federal guidelines. Holmes's appeals challenging her November 2022 convictions on four counts were progressively denied. The U.S. Court of Appeals for the Ninth Circuit upheld the convictions and sentences on February 24, 2025, rejecting arguments that trial evidence was improperly admitted and that juror bias invalidated the verdict. A subsequent for en banc rehearing was unanimously denied on May 8, 2025, exhausting her direct appeal options short of a potential U.S. . In a 2025 interview conducted via from , Holmes described her incarceration as "hell and ," citing separation from her two young children and harsh living conditions, while expressing defiance and intent to continue fighting her case. She reiterated in March 2025 her commitment to "fight for my freedom," framing ongoing legal efforts as necessary despite the upheld convictions. As of October 2025, no further reductions or releases have been granted, with her case focused on sentencing mercy rather than overturning the findings.

Public Image and Promotion

Rise as a Tech Visionary

Elizabeth Holmes founded Theranos in 2003 at the age of 19, shortly after beginning her freshman year at Stanford University studying chemical engineering. She dropped out of Stanford to dedicate herself fully to the company, which aimed to develop a portable device capable of conducting hundreds of blood tests using just a few drops of blood from a finger prick. This vision promised to disrupt traditional laboratory-based diagnostics by enabling rapid, affordable testing at the point of care, drawing inspiration from Holmes's frustration with venipuncture during a trip to Beijing. Theranos secured early funding starting with $6.9 million in 2004, achieving a $30 million valuation, followed by subsequent rounds that propelled its growth. By , the company reached status with a $1 billion valuation after additional investments, attracting high-profile backers including media mogul and venture firms. Holmes cultivated an image of relentless innovation, emulating figures like through her black turtleneck attire and emphasis on secrecy to protect proprietary technology, which fueled perceptions of her as a transformative entrepreneur. Media coverage amplified Holmes's rise, with a 2014 Fortune profile portraying her as a visionary CEO leading a $9 billion company revolutionizing healthcare. named her the youngest self-made female billionaire in 2014, estimating her at $4.5 billion based on Theranos's valuation. She received accolades such as in 2015, reinforcing her status as a tech icon amid widespread enthusiasm for her purported breakthrough in blood testing. These portrayals often highlighted her youth, determination, and potential to democratize medical diagnostics, though they relied heavily on company-provided demonstrations rather than independent verification.

Media Appearances and Awards

Elizabeth Holmes received extensive positive media coverage during Theranos' ascent, appearing on the covers of major publications including Forbes, Fortune, Inc., and T: The New York Times Style Magazine in 2014. These features highlighted her as a visionary entrepreneur disrupting healthcare through innovative blood-testing technology. Holmes also featured in interviews and videos, such as a 2015 Forbes conversation where she was described as America's richest self-made woman and youngest female billionaire at age 31. In terms of awards and recognitions, Forbes named Holmes the world's youngest self-made female billionaire in 2014, valuing her stake in Theranos at $4.5 billion when she was 30 years old. She received the Forbes Under 30 Doers Award and was ranked #73 on its 2015 list of the most powerful women. Time magazine included her among the 100 most influential people in the world in 2015. Additionally, in 2015, Holmes was honored with Glamour magazine's Woman of the Year award, presented by actor Jared Leto. These accolades were predicated on Theranos' claimed breakthroughs, which subsequent investigations revealed to be unsubstantiated.

Criticisms of Hype and Self-Promotion

Holmes cultivated a public persona modeled after , adopting black turtlenecks as a —reportedly at the of a former Apple executive—and a deepened speaking voice to convey gravitas, while framing Theranos' blood-testing device as the "iPod of personal health." Critics, including journalists and former associates, later described these as calculated affectations designed to evoke innovative genius without corresponding technological proof, enabling her to secure a $9 billion company valuation by 2014 primarily through charismatic storytelling rather than empirical demonstrations. Her self-promotion extended to assembling a high-profile advisory board comprising figures like and , whose political stature was leveraged for prestige despite their lack of biotech expertise, a move analysts critiqued as prioritizing endorsement over rigorous oversight to sustain investor allure. Media outlets amplified this image, with a December 2014 New Yorker profile portraying Holmes as a healthcare revolutionary capable of performing hundreds of tests from a single drop of at a fraction of traditional costs—claims under $3 per test that promised to upend the $75 billion industry. In 2015, hailed her as the youngest self-made female based on the inflated valuation, though subsequent revealed the assessment relied on unverified hype rather than audited performance metrics. Skepticism from figures like pathologist Adam Schechter, who in 2005 questioned the feasibility of the proprietary Edison device's claims during early partnerships, was dismissed by Holmes as competitive sabotage, with citing secrecy to avoid transparent validations or peer-reviewed data. Demonstrations for investors and media often involved surreptitious use of commercial analyzers or diluted samples rather than the vaunted "" technology, tactics of exposed in October 2015 as emblematic of hype eclipsing reality. responded aggressively, denouncing the reporting as "factually and scientifically erroneous" sourced from "disgruntled" ex-employees, threatening legal action against critics, and even leading staff chants targeting Carreyrou, actions observers faulted for entrenching a that stifled dissent and perpetuated unsubstantiated promotion. Regulatory probes, including the FDA's 2015 restriction of the Edison to a single test due to inaccuracy risks, underscored how self-promotional opacity—such as vague descriptions of the process as "a chemistry... generating a signal"—delayed , with Holmes attributing external doubts to industry incumbents rather than addressing device failures documented in internal logs showing error rates exceeding 10% in proficiency tests. Carreyrou and others argued this pattern exemplified a broader tendency to reward narrative over evidence, where Holmes' evasion tactics transformed initial exaggeration into systemic deception, eroding trust in startup claims absent independent verification.

Personal Life

Romantic Relationships and Marriage

Elizabeth Holmes began a romantic relationship with Ramesh "Sunny" Balwani in approximately 2004, following their initial meeting in , , in 2002 when Holmes was 18 years old and Balwani was 37. By July 2005, the couple was cohabiting in Balwani's Palo Alto condominium, and their partnership remained undisclosed to board members and investors during Balwani's tenure as the company's president and COO from 2015 onward. The relationship, which lasted over a decade until around 2015, became a point of contention in Holmes's 2021 criminal trial, where she testified that Balwani had subjected her to emotional, psychological, and , claims that Balwani has denied. Following the collapse of in 2018, Holmes entered a relationship with William "Billy" , son of the Evans Hotel Group owners, whom she met at a party in 2017. The couple became engaged in 2018 and held a private commitment ceremony in 2019, though they have not entered into a legal , with Holmes stating in 2025 that their bond transcends formal paperwork and that they may marry in the future. Holmes and Evans have two children: a son, William Holmes Evans, born in July 2021, and a daughter, Invicta, born in early 2023. Evans has remained supportive amid Holmes's legal proceedings, including her incarceration beginning in May 2023, and the family relocated to prior to her imprisonment.

Children and Family Dynamics

Holmes married William "Billy" Evans, an heir to the Evans Hotel Group, in a private ceremony in 2019. The couple welcomed their first child, son William Holmes Evans, on July 10, 2021, in , shortly before Holmes' criminal fraud trial began in September 2021. Holmes had announced her in March 2021 while free on , and the birth occurred amid ongoing legal proceedings related to her convictions. In late 2022, Holmes gave birth to their second child, a daughter whose name has not been publicly disclosed. Her attorneys cited the recent birth in a March 2023 filing to request a delay in her reporting to , arguing for additional time to arrange childcare and before beginning her 11-year sentence for wire fraud and . The request was partially granted, allowing a brief postponement, but Holmes ultimately reported to FCI Bryan in on May 30, 2023, leaving primary custody of the children with Evans. Public details on family dynamics remain limited, as Holmes has prioritized for her young children amid her legal battles. Evans, described as supportive during her and appeals, has handled day-to-day while Holmes serves her sentence; court filings and statements indicate Holmes maintains contact with her , including her parents Christian and Noel Holmes, who have provided emotional support. Experts note that parental incarceration can lead to long-term emotional challenges for children, though specific impacts on Holmes' are not publicly documented. In early 2025, Holmes referenced her children in legal communications, emphasizing her role as a despite imprisonment.

Cultural Depictions and Legacy

Books, Documentaries, and Films

The primary book chronicling the Theranos scandal is Bad Blood: Secrets and Lies in a Silicon Valley Startup by John Carreyrou, published on May 21, 2018, by Alfred A. Knopf. Drawing from Carreyrou's investigative reporting as a Wall Street Journal journalist, the book details Holmes's founding of Theranos in 2003, the company's fraudulent claims of revolutionary blood-testing technology capable of conducting hundreds of tests from a single drop of blood, and the internal cover-ups that persisted until whistleblowers exposed the deceptions in 2015. It emphasizes empirical evidence of Theranos's inability to deliver functional devices, with prototypes failing basic validation and results fabricated through partnerships with commercial labs like Quest Diagnostics. Documentaries include The Inventor: Out for Blood in , directed by and released on March 11, 2019, via . The film incorporates interviews with former employees, investors, and regulators, alongside archival footage of Holmes's public presentations, to illustrate the causal chain from hype-driven valuations exceeding $9 billion in to regulatory scrutiny and collapse by 2018. Another is Valley of Hype: The Culture that Built Elizabeth Holmes, a directed by Reg Ho

Broader Impact on Biotech and Startup Culture

The scandal, which unraveled publicly in after revelations of fabricated technology claims, prompted a reevaluation of unchecked hype in Silicon Valley's , particularly in biotech where unverified prototypes can attract massive funding. Investors and entrepreneurs began questioning the "fake it till you make it" ethos that propelled Holmes' company to a $9 billion valuation despite lacking functional blood-testing devices capable of the promised tests from a single drop. This exposure highlighted systemic vulnerabilities, including overreliance on charismatic founders, celebrity endorsements from figures like and James Mattis, and boards lacking technical expertise, which failed to scrutinize Holmes' assertions. In biotech specifically, the fallout intensified demands for rigorous technical before funding, as venture capitalists recognized the risks of opaque "" innovations in regulated fields like diagnostics, where intersects with investor returns. Post-2015, while overall biotech venture funding surged—digital investments tripled from 2016 levels by mid-2021—investors adopted more stringent validation protocols, such as independent lab testing and demonstrations, to avoid Theranos-like . Companies in the sector, including those in liquid biopsy and , faced heightened scrutiny from bodies like the FDA and SEC, contributing to slower paths to for high-risk claims but fostering through whistleblower incentives and ethical reforms. The scandal's legacy in startup culture underscores a tension between and prevention: it curbed tolerance for unsubstantiated bravado, encouraging diverse, expert-led boards and transparent metrics over narrative-driven pitches, yet critics argue it did not fundamentally alter Silicon Valley's reward for disruption, as evidenced by continued valuations in unproven tech. Holmes' in January 2022 on charges reinforced legal deterrents, prompting founders to prioritize empirical proof over , though some biotech leaders contend excessive caution could stifle genuine breakthroughs in capital-intensive fields. Overall, served as a catalyst for causal , linking founder incentives directly to verifiable outcomes rather than promotional mystique.

Debates on Fraud, Innovation, and Accountability

Elizabeth Holmes was convicted on January 4, 2022, of one count of to commit wire and three counts of wire against investors, following a scheme that defrauded them of over $700 million through false representations about the company's blood-testing technology. The jury acquitted her on charges related to defrauding patients, citing insufficient of harm or of test inaccuracies affecting care. On November 18, 2022, U.S. District Judge sentenced Holmes to 135 months in prison, three years of supervised release, and joint restitution of $452 million with co-defendant Balwani, emphasizing the "extraordinary " that prioritized personal gain over . Her conviction was upheld by the Ninth Circuit Court of Appeals on February 24, 2025, rejecting arguments that trial prejudiced the jury. Debates over Holmes's intent center on whether her actions constituted deliberate or stemmed from over-optimism fueled by startup pressures, with prosecutors highlighting evidence of efforts to suppress Wall Street Journal reporting on Theranos's use of commercial analyzers to fake results, rather than proprietary devices capable of processing finger-prick blood samples. Critics argue the was systemic, involving falsified demonstrations, regulatory misrepresentations, and a of that silenced employee whistleblowers, as testified during . Defenders, including some observers, contend that Holmes's vision for disruptive diagnostics was genuine but undermined by technical hurdles, though empirical evidence—such as failed internal validations and reliance on diluted samples—undermines claims of viable , revealing instead a mirage sustained by hype. The purported innovation of Theranos's Edison device, which claimed to run hundreds of tests from a single drop of blood with minimal , clashed with : independent analyses showed the produced unreliable results due to insufficient sample volume and lacked peer-reviewed validation, prompting early from hematologists who noted physical limits on detecting low-concentration analytes. Experts attribute the not to isolated errors but to foundational flaws, including avoidance of standard diagnostics protocols and over-reliance on , which delayed detection until regulatory scrutiny in 2015 exposed manipulated proficiency tests. While some debate whether Theranos accelerated biotech scrutiny, leading to stricter FDA oversight, the consensus among industry analysts is that it exemplified masquerading as breakthrough, eroding trust without yielding transferable advancements. Accountability discussions highlight as a cautionary case for Silicon Valley's "fake it till you make it" ethos, where celebrity boards lacking technical expertise—composed of figures like and James Mattis—failed to probe claims, enabling unchecked exaggeration. Venture capital's emphasis on narrative over amplified risks, with $945 million raised on unproven tech, prompting calls for enhanced ethical training and independent audits in startups. Holmes's conviction imposed personal liability, but broader reforms debate regulatory gaps, such as CLIA lab certifications that exploited through secrecy, versus over-regulation stifling genuine innovation; analysts note the scandal's outlier status, as most biotech failures stem from legitimate R&D setbacks rather than . Ultimately, the episode underscores causal links between unchecked ambition, poor , and investor losses, reinforcing demands for transparency without excusing individual culpability.

References

  1. https://www.businessinsider.com/theranos-founder-ceo-elizabeth-holmes-life-story-bio-2018-4
  2. https://www.forbes.com/profile/elizabeth-holmes/
  3. https://www.justice.gov/usao-ndca/us-v-elizabeth-holmes-et-al
  4. https://www.justice.gov/usao-ndca/pr/elizabeth-holmes-sentenced-more-11-years-defrauding-theranos-investors-hundreds
  5. https://www.cnbc.com/2025/05/08/elizabeth-holmes-theranos-fraud-appeal.html
  6. https://www.biography.com/business-leaders/elizabeth-holmes
  7. https://people.com/all-about-elizabeth-holmes-parents-11678416
  8. https://www.houstonchronicle.com/news/houston-texas/crime/article/elizabeth-holmes-prison-bryan-texas-theranos-trial-18125550.php
  9. https://www.the-sun.com/news/4812825/elizabeth-holmes-parents-where-are-they/
  10. https://www.bbc.com/news/business-58336998
  11. https://www.biospace.com/as-a-child-elizabeth-holmes-was-guarded-and-private-school-friend-tells-abc
  12. https://www.refinery29.com/en-us/elizabeth-holmes-family-worth-rich-parents-grandparents
  13. https://www.houstonchronicle.com/news/houston-texas/trending/article/elizabeth-holmes-people-magazine-interview-20165628.php
  14. https://www.cnn.com/2022/07/07/tech/theranos-rise-and-fall
  15. https://fortune.com/2014/06/12/theranos-blood-holmes/
  16. https://www.newsweek.com/dropout-elizabeth-holmes-theranos-fraud-stanford-1683992
  17. https://theconversation.com/elizabeth-holmes-theranos-scandal-has-more-to-it-than-just-toxic-silicon-valley-culture-114102
  18. https://www.oxygen.com/true-crime-buzz/when-did-elizabeth-holmes-get-the-idea-for-theranos
  19. https://www.integrityline.com/expertise/blog/elizabeth-holmes-theranos/
  20. https://ideas.darden.virginia.edu/theranos-darden-case
  21. https://www.cnbc.com/2015/09/29/fear-of-blood-inspired-youngest-female-billionaire.html
  22. https://www.cnn.com/2022/01/04/tech/elizabeth-holmes-rise-and-fall
  23. https://www.reddit.com/r/Theranos/comments/13jd2b2/elizabeths_first_idea_for_the_arm_patch_was/
  24. https://www.businessinsider.com/stanford-professor-phyllis-gardner-on-theranos-and-elizabeth-holmes-2019-3
  25. https://www.mercurynews.com/2019/06/03/she-saw-through-elizabeth-holmes-now-stanford-professor-is-star-in-theranos-saga/
  26. https://www.wired.com/2016/05/everything-need-know-theranos-saga-far/
  27. https://www.newyorker.com/magazine/2014/12/15/blood-simpler
  28. https://www.businessinsider.com/the-history-of-silicon-valley-unicorn-theranos-and-ceo-elizabeth-holmes-2018-5
  29. https://www.refinery29.com/en-us/2019/03/224904/theranos-edison-machine-blood-test-technology-explained
  30. https://www.cliffsnotes.com/study-notes/27523709
  31. https://www.vanityfair.com/news/2016/08/elizabeth-holmes-presentation-theranos-data
  32. https://www.neoteryx.com/microsampling-blog/three-lessons-from-the-fall-of-theranos
  33. https://www.reuters.com/world/us/rise-fall-theranos-founder-elizabeth-holmes-2022-01-04/
  34. https://shareholderoppression.com/blog/bad-blood-the-trial-and-ndas
  35. https://www.forbes.com/sites/petercohan/2016/12/01/how-theranoss-big-investors-were-taken/
  36. https://news.crunchbase.com/health-wellness-biotech/theranos-elizabeth-holmes-trial-investors-board/
  37. https://www.reddit.com/r/NoStupidQuestions/comments/1gvo97b/how_did_elizabeth_holmes_manage_to_trick_so_many/
  38. https://escalon.services/blog/startups/elizabeth-holmes-conviction-is-a-wakeup-call-for-startups-and-investors
  39. https://fm.cnbc.com/applications/cnbc.com/resources/editorialfiles/2018/03/14/comp-pr2018-41-theranos-holmes.pdf
  40. https://qz.com/2074304/how-safeway-and-walgreens-fell-for-the-theranos-pipe-dream
  41. https://www.fiercebiotech.com/medical-devices/safeway-severs-ties-theranos-as-350m-deal-collapses
  42. https://www.cnbc.com/2021/10/12/safeway-ex-ceo-we-did-at-least-100-hours-of-diligence-on-theranos.html
  43. https://www.usatoday.com/story/tech/2015/11/12/safeway-retreating-theranos-deal-report-says/75633284/
  44. https://www.walgreensbootsalliance.com/news-media/press-releases/2013/theranos-selects-walgreens-as-a-long-term-partner-through-which-to-offer-its-new-clinical-laboratory-service
  45. https://qz.com/walgreens-amazon-theranos-cvs-rite-aid-opioid-crisis-re-1851768411
  46. https://www.wsj.com/livecoverage/elizabeth-holmes-trial-theranos/card/0l51TSgfoFELH8p5VT6c
  47. https://fortune.com/2016/05/26/walgreens-didnt-verify-theranos/
  48. https://www.nytimes.com/2016/04/22/business/a-once-avid-ally-walgreens-is-struggling-to-shake-off-theranos.html
  49. https://www.supermarketnews.com/nonfood-pharmacy/walgreens-agrees-to-pay-44m-to-theranos-customers
  50. https://abcnews.go.com/Business/theranos-employees-describe-culture-secrecy-elizabeth-holmes-startup/story?id=60544673
  51. https://www.vanityfair.com/news/2016/07/theranos-culture-of-secrecy-comes-back-to-haunt-it
  52. https://www.science.org/content/blog-post/inside-theranos-yikes
  53. https://isb.idaho.gov/blog/theranos-and-the-tale-of-the-disappearing-board-of-directors/
  54. https://www.wsj.com/podcasts/google-news-update/in-holmes-trial-ex-theranos-workers-describe-secretive-culture/54a3d5bd-745f-4fdf-af14-19fd3b196564
  55. https://www.wired.com/story/a-new-look-inside-theranos-dysfunctional-corporate-culture/
  56. https://scholarship.law.vanderbilt.edu/cgi/viewcontent.cgi?article=2236&context=faculty-publications
  57. https://www.eaglehillconsulting.com/insights/theranos-toxic-culture-lessons/
  58. https://www.medicaldevice-network.com/features/theranos-failure-timeline/
  59. https://www.sunsethq.com/blog/why-did-theranos-fail
  60. https://pulse.icdm.com.my/article/what-went-wrong-with-theranos/
  61. https://www.cnbc.com/2021/09/15/former-theranos-employee-erika-cheung-edison-machines-failed-tests.html
  62. https://www.cnn.com/2021/09/15/tech/elizabeth-holmes-trial-witness-erika-cheung
  63. https://www.wsj.com/articles/theranos-devices-often-failed-accuracy-requirements-1459465578
  64. https://www.massdevice.com/former-theranos-scientist-testifies-to-blood-test-inaccuracies-prior-to-walgreens-deal-in-elizabeth-holmes-trial/
  65. https://www.fdli.org/2023/06/united-states-v-elizabeth-holmes-and-ramesh-balwani/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC8979578/
  67. https://www.theregister.com/2021/10/21/theranos_machine_trial/
  68. https://www.biospace.com/theranos-whistleblower-testifies-the-company-manipulated-data-to-achieve-desired-quality-reports
  69. https://www.wsj.com/livecoverage/elizabeth-holmes-trial-theranos/card/u0WLLvDzUeIQTZ98jqf9
  70. https://www.nytimes.com/2021/11/22/technology/elizabeth-holmes-evidence-prosecution.html
  71. https://www.fiercebiotech.com/medtech/theranos-trial-elizabeth-holmes-admits-to-using-altered-siemens-analyzers-for-blood-tests
  72. https://www.biospace.com/federal-report-reveals-theranos-devices-often-failed-accuracy-requirements
  73. https://pubs.sciepub.com/jbe/12/1/1/
  74. https://fortune.com/2015/10/27/fda-theranos-lab-inspection-findings/
  75. https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/cpdd.374
  76. https://democrats-energycommerce.house.gov/sites/evo-subsites/democrats-energycommerce.house.gov/files/documents/FDA%2520Califf%2520Theranos%2520Letter%25202016%252007%252026.pdf
  77. https://www.theguardian.com/technology/2016/jul/08/theranos-elizabeth-holmes-banned-medical-lab
  78. https://texaslawbook.net/inside-a-whistleblowers-ordeal-tyler-shultz-details-the-battle-to-expose-theranos/
  79. https://www.acfe.com/fraud-magazine/all-issues/issue/article?s=2019-septoct-tyler-shultz-theranos-whistleblower-cover
  80. https://www.npr.org/2022/01/05/1070474663/theranos-whistleblower-tyler-shultz-elizabeth-holmes-verdict-champagne
  81. https://www.statnews.com/2019/05/01/from-protegee-to-whistleblower-a-former-theranos-scientist-says-elizabeth-holmes-should-come-forward-and-apologize/
  82. https://techworkerhandbook.org/media/erika-cheung-theranos-2015/
  83. https://www.wsj.com/news/collection/theranos-coverage-ea13b200
  84. https://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901
  85. https://www.wsj.com/tech/theranos-and-elizabeth-holmes-history-of-the-wsj-investigation-11629815129
  86. https://www.theguardian.com/technology/2021/aug/28/elizabeth-holmes-theranos-trial-john-carreyrou
  87. https://www.nytimes.com/2015/10/28/business/theranos-quality-control-was-questioned-by-fda.html
  88. https://www.theverge.com/2015/10/27/9621026/fda-theranos-lab-quality-inspection-elizabeth-holmes
  89. https://www.sec.gov/newsroom/press-releases/2018-41
  90. https://www.justice.gov/usao-ndca/pr/theranos-founder-and-former-chief-operating-officer-charged-alleged-wire-fraud-schemes
  91. https://www.sec.gov/files/litigation/complaints/2018/comp-pr2018-41-theranos-holmes.pdf
  92. https://www.theguardian.com/technology/2016/oct/06/theranos-lab-closures-walgreens-centers-layoffs-elizabeth-holmes
  93. https://www.npr.org/sections/thetwo-way/2016/10/06/496858408/theranos-is-shutting-its-blood-test-facilities-shedding-40-percent-of-workers
  94. https://www.reuters.com/article/business/healthcare-pharmaceuticals/theranos-founder-elizabeth-holmes-steps-down-as-ceo-idUSL4N1TH5TY/
  95. https://www.wsj.com/articles/elizabeth-holmes-steps-down-as-theranos-ceo-1529096366
  96. https://www.cnbc.com/2018/06/15/theranos-chief-elizabeth-holmes-arrested-on-federal-criminal-charges-.html
  97. https://www.nytimes.com/2018/09/05/health/theranos-shutting-down.html
  98. https://www.cnbc.com/2018/09/05/theranos-shutting-down--look-back-at-revelations-from-bad-blood.html
  99. https://www.npr.org/2021/08/30/1031314018/elizabeth-holmes-theranos-fraud-trial
  100. https://abcnews.go.com/Business/theranos-founder-elizabeth-holmes-criminal-trial-begins/story?id=79727093
  101. https://www.cnn.com/2022/01/03/tech/theranos-trial-elizabeth-holmes-takeaways
  102. https://www.nytimes.com/2021/12/31/business/elizabeth-holmes-trial-numbers.html
  103. https://www.cnbc.com/2022/01/03/jurors-in-holmes-trial-remain-deadlocked-on-three-of-11-fraud-counts.html
  104. https://www.justice.gov/usao-ndca/pr/theranos-founder-elizabeth-holmes-found-guilty-investor-fraud
  105. https://www.nytimes.com/2022/01/03/technology/elizabeth-holmes-guilty.html
  106. https://www.acfe.com/acfe-insights-blog/blog-detail?s=elizabeth-holmes-found-guilty-on-four-charges-of-fraud
  107. https://www.npr.org/2023/05/30/1178728092/elizabeth-holmes-prison-sentence-theranos-fraud-silicon-valley
  108. https://www.prisonology.com/blog/the-first-step-act-shortens-federal-prison-sentences-including-elizabeth-holmes
  109. https://www.theguardian.com/us-news/2023/jul/10/elizabeth-holmes-11-year-prison-sentence-shortened-by-two-years
  110. https://www.nbcnews.com/news/us-news/elizabeth-holmes-prison-release-date-rcna149825
  111. https://cdn.ca9.uscourts.gov/datastore/opinions/2025/02/24/22-10312.pdf
  112. https://abcnews.go.com/Business/theranos-founder-elizabeth-holmes-conviction-upheld-us-appeals/story?id=119135714
  113. https://law.justia.com/cases/federal/appellate-courts/ca9/22-10312/22-10312-2025-02-24.html
  114. https://news.bloomberglaw.com/litigation/elizabeth-holmes-fraud-conviction-upheld-by-the-ninth-circuit
  115. https://www.courthousenews.com/ninth-circuit-denies-elizabeth-holmes-request-for-rehearing/
  116. https://abc7news.com/post/former-theranos-ceo-elizabeth-holmes-petition-have-future-hearings-fraud-conviction-appeal-unanimously-denied-court/16363337/
  117. https://www.theguardian.com/technology/2023/apr/11/elizabeth-holmes-begin-prison-sentence-end-of-month
  118. https://www.corrections1.com/legal/elizabeth-holmes-seeks-sentence-reduction-citing-rehabilitation-work-in-prison
  119. https://www.theguardian.com/us-news/article/2024/may/07/elizabeth-holmes-prison-sentence
  120. https://sfist.com/2025/06/13/with-appeal-options-nearly-exhausted-elizabeth-holmes/
  121. https://apnews.com/article/elizabeth-holmes-theranos-fraud-conviction-appeal-193bb0a0bfe306e796acd13c151e705c
  122. https://www.latimes.com/business/story/2025-02-24/elizabeth-holmes-fraud-conviction-upheld-by-appeals-court
  123. https://www.yahoo.com/news/theranos-fraudster-elizabeth-holmes-loses-193130977.html
  124. https://people.com/elizabeth-holmes-breaks-her-silence-in-first-interview-from-prison-it-s-been-hell-and-torture-exclusive-8789737
  125. https://nypost.com/2025/02/12/business/elizabeth-holmes-talks-prison-life-hell-and-torture-in-first-interview-since-theranos-conviction/
  126. https://people.com/elizabeth-holmes-defiantly-vows-to-fight-for-my-freedom-exclusive-11690947
  127. https://www.investopedia.com/articles/investing/020116/theranos-fallen-unicorn.asp
  128. https://www.teachmewallstreet.com/scandal-of-elizabeth-holmes
  129. https://www.nytimes.com/2021/11/18/technology/elizabeth-holmes-theranos-trial.html
  130. https://www.vox.com/2015/10/26/11620036/theranos-ceo-elizabeth-holmess-five-best-cover-story-appearances
  131. https://www.seattletimes.com/nation-world/the-magazine-story-that-made-elizabeth-holmes-famous-could-now-help-send-her-to-prison/
  132. https://www.forbes.com/video/4543269142001/a-conversation-with-theranos-ceo-elizabeth-holmes/
  133. https://www.today.com/news/elizabeth-holmes-now-rcna191899
  134. https://variety.com/2022/tv/news/jared-leto-elizabeth-holmes-amanda-seyfried-the-dropout-1235292949/
  135. https://www.forbes.com/sites/matthewherper/2016/06/01/from-4-5-billion-to-nothing-forbes-revises-estimated-net-worth-of-theranos-founder-elizabeth-holmes/
  136. https://www.businessinsider.com/elizabeth-holmes-theranos-steve-jobs-obsession-2018-5
  137. https://www.forbes.com/sites/dereklidow/2018/06/18/the-theranos-scandal-what-happens-when-you-misunderstand-steve-jobs/
  138. https://www.businessinsider.com/theranos-founder-elizabeth-holmes-deep-voice-2019-3
  139. https://www.theguardian.com/commentisfree/2018/jun/03/theranos-elizabeth-holmes-media-emperors-new-startup
  140. https://www.forbes.com/pictures/56d4357fe4b0c144a7f677e9/elizabeth-holmes/
  141. https://www.vox.com/2015/10/20/9576501/theranos-elizabeth-holmes
  142. https://www.theverge.com/2021/9/28/22697263/john-carreyrou-theranos-elizabeth-holmes-decoder
  143. https://www.businessinsider.com/elizabeth-holmes-sunny-balwani-relationship-timeline-2023-5
  144. https://www.vanityfair.com/hollywood/2022/03/elizabeth-holmes-sunny-balwani-the-dropout
  145. https://abcnews.go.com/Business/sunny-balwani-elizabeth-holmes-former-partner-sentenced-theranos/story?id=94579128
  146. https://www.aljazeera.com/economy/2021/11/30/read-elizabeth-holmess-and-sunny-balwanis-newly-released-texts
  147. https://www.scmp.com/magazines/style/celebrity/article/3169968/inside-elizabeth-holmes-and-billy-evans-marriage-theranos
  148. https://people.com/crime/who-is-billy-evans-elizabeth-holmes-husband/
  149. https://people.com/elizabeth-holmes-relationship-billy-evans-hotel-heir-exclusive-11679100
  150. https://people.com/elizabeth-holmes-kids-everything-to-know-11678732
  151. https://timesofindia.indiatimes.com/life-style/relationships/love-sex/how-elizabeth-holmes-met-and-fell-for-billy-evans-inside-their-love-and-family-life/articleshow/121080513.cms
  152. https://news.northeastern.edu/2023/06/12/elizabeth-holmes-incarceration-children/
  153. https://abcnews.go.com/Business/theranos-founder-elizabeth-holmes-welcomes-1st-child-partner/story?id=79298331
  154. https://www.aol.com/elizabeth-holmes-gotten-pregnant-twice-181700511.html
  155. https://www.theguardian.com/technology/2023/mar/01/elizabeth-holmes-second-child-theranos-prison-sentence-delay
  156. https://www.yahoo.com/news/incarcerated-elizabeth-holmes-breaks-silence-140029637.html
  157. https://www.penguinrandomhouse.com/books/549478/bad-blood-by-john-carreyrou/
  158. https://www.hulu.com/movie/the-inventor-out-for-blood-in-silicon-valley-c39a816d-b3bd-4a1b-a17e-ac770e7f7785
  159. https://www.wired.com/story/what-biotech-ceos-and-their-funders-learned-from-the-theranos-debacle/
  160. https://www.bbc.com/news/technology-58469882
  161. https://www.politico.com/newsletters/future-pulse/2021/08/11/has-health-tech-investing-changed-since-theranos-797079
  162. https://vaultinum.com/blog/theranos-a-reminder-of-the-importance-of-technical-due-diligence
  163. https://www.gsb.stanford.edu/insights/what-can-we-learn-downfall-theranos
  164. https://esmt.berlin/knowledge/theranos-strategy-lesson
  165. https://insights.som.yale.edu/insights/theranos-teaches-silicon-valley-hard-lesson-about-accountability
  166. https://www.politico.com/news/2023/05/28/elizabeth-holmes-motives-prison-theranos-00099112
  167. https://insights.som.yale.edu/insights/three-questions-dr-greg-licholai-on-biotech-after-theranos
  168. https://www.theverge.com/22834348/theranos-blood-testing-innovation-drop-holmes
  169. https://www.vox.com/2015/10/31/9646356/theranos-peer-review-evidence
  170. https://www.youtube.com/watch?v=zoj1tk1xetQ
  171. https://www.reddit.com/r/Theranos/comments/zhx8k6/the_long_term_impact_of_the_theranos_fraud_on_the/
  172. https://corpgov.law.harvard.edu/2021/11/16/elizabeth-holmes-and-the-mythology-of-silicon-valley/
  173. https://www.bu.edu/rbfl/2023/05/17/theranos-is-a-symptom-of-a-larger-problem-within-vc-backed-startups/
  174. https://lrn.com/blog/key-takeaways-ethics-compliance-theranos-trial-elizabeth-holmes
  175. https://www.forbes.com/sites/benjaminlaker/2023/06/18/elizabeth-holmes-fall-from-grace-a-case-study-in-leadership-strategy-and-corporate-accountability/
Add your contribution
Related Hubs
User Avatar
No comments yet.